Speaker Profile
Ph.D., Professor, Stanford
Biography
Dr. Garry P. Nolan is the Rachford and Carlota A. Harris Professor in the Department of Pathology at Stanford University School of Medicine. Trained with Leonard Herzenberg (Ph. D.) and Nobel laureate David Baltimore (postdoc), he is known for cloning and characterizing NF-κB p65RelA and developing rapid retroviral production systems. Author of over 350 papers and holder of 50 U. S. patents, he has received multiple honors, including the Teal Innovator Award, FDA BAAA, and Nature Publishing Groups Outstanding Research Achievement. His research spans hematopoiesis, cancer, autoimmunity, inflammation, and systems immunology, with a focus on single-cell analysis technologies such as CyTOF, MIBI, and CODEX. Dr. Nolan has founded or co-founded multiple biotech companies, with several acquired by industry leaders. His current work applies high-dimensional imaging and cytometry to deepen understanding of immune function, pathogen response, and cancer biology, aiming to improve disease management and clinical outcomes.
Session Abstract – PMWC 2026 Silicon Valley
Track Chair:
Victor Velculescu, Johns Hopkins University
PMWC Award Ceremony
• Daniel De Carvalho, University of Toronto
From Mutation to Methylation: The Next Wave of Liquid Biopsy Biomarkers
• Chair: Victor Velculescu, Johns Hopkins University
• Daniel De Carvalho, University of Toronto
• Stephen Master, CHOP/U Penn
• Gordon Sanghera, Oxford Nanopore Technologies
Advancing Minimal Residual Disease Detection Through cfDNA & cfRNA Profiling
• Chair: Luis Diaz, Memorial Sloan Kettering Cancer Center
• Anne-Renee Hartman, Adela
• Minetta Liu, Natera
• Rita Shaknovich, Agilent
• Ajay Gannerkote, Integrated DNA Tech
AI-Informed Biomarker Trials: Turning Early Signals into Actionable Designs
• Chair: Manish Kohli, University of Utah
• Eric Klein, GRAIL
• Sarah Moseley, DELFI Diagnostics
• Samuel Levy, ClearNote Health
Role of AI in Liquid Biopsies & Cancer Detection
• Chair: Amoolya Singh, DELFI Diagnostics
• Ron Andrews, Dxcover
• Pankaj Vats, NVIDIA
• Paul Shi, Amgen
• Christopher Troll, Claret Bioscience
Integrating Genetic Risk with Early Detection: A Precision Prevention Framework for Cardiovascular Disease
• Paolo Di Domenico, Allelica
AI-Driven Metagenomic and Host RNA Profiling for Precision Diagnosis of Infections
• Charles Chiu, UCSF
AI-Driven Host–Pathogen Signatures from Plasma cfDNA: Bridging Infection Biology and Early Diagnostics
• Sivan Bercovici, Karius
Ultra-Sensitive Multimodal Liquid Biopsy for Early Cancer Detection: AI-Driven Signal Profiling
• John Sninsky, CellMax Life
Overcoming Limits of Traditional cfDNA Assays Using Active Chromatin
• Diana Abdueva, Aqtual
Whole-genome methylome-based early cancer signal detection
• Sally Mackenzie, EpiMethyl Analytics
BrainSee Sees the Brain: FDA-Approved AI for Predicting Modifiable Risk of Developing Alzheimer’s Within Five Year
• Padideh Kamali-Zare, Darmiyan
